Join to View Full Profile
Princeton PikeLawrence, NJ 08648
Dr. Acevedo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Angelic Acevedo, MD, is a healthcare professional located in NJ, specializing in Oncology research. She graduated in the class of 2000 from UAG. With over 20 yrs of experience, she’s currently the Clinical Development Lead for BMS’s KRAS G12C inhibitor, Krazati, in CRC. Dr. Acevedo has also contributed to notable publications across NSCLC, including the Checkmate 169, -171, -817 and -592 studies.
Education & Training
University of Puerto RicoInternship, Emergency Medicine, 2000 - 2001
Universidad Autonoma de GuadalajaraClass of 2000
Certifications & Licensure
PR State Medical License 2001 - 2025
Clinical Trials
- An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC Start of enrollment: 2015 Apr 29
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2015 Aug 05
- Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
- Join now to see all
Publications & Presentations
PubMed
- 36 citationsFirst-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckM...Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu
Journal for Immunotherapy of Cancer. 2023-02-01 - 120 citationsCheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populationsEnriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, Manuel Cobo, Konstantin Laktionov
European Journal of Cancer. 2020-02-03
Journal Articles
- Checkmate 169: Safety and Efficacy of Nivolumab in Canadian Patients with Pretreated Advanced NSCLC, Including Patients Aged >= 70 yrs or with ECOG PS 2Rosalyn Juergens, Quincy Chu, Jeffrey Rothenstein, Fkavia De Angelis, Shantanu Banerji, Katherine Marquis, Delia Sauciuc, Paul Begin, Nicholas Finn, Vera Hirsh, Aamir ..., 18th World Conference on Lung Cancer of the IASLC, 10/2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
